The research focused on a critical and understudied window of life: the neonatal period. Children with chronic kidney disease, including those with PKD, are known to experience neurocognitive difficulties even before they ever require dialysis or transplantation, suggesting that the disease process itself, acting during early brain development, may lay the groundwork for later cognitive problems. Prior human neuroimaging work had hinted at one possible culprit: iron. Quantitative T2* magnetic resonance imaging, a technique sensitive to the magnetic properties of iron stored in tissue, had shown shorter T2* relaxation times in the brains of children and young adults with kidney disease, a signal interpreted as increased iron deposition. What had been missing was any animal evidence confirming that kidney disease actually causes iron to accumulate in the brain during early development, and any histological validation that the imaging signal truly reflects iron rather than some other tissue change.

To close that gap, the team employed a conditional Pkd2 knockout mouse, a model in which the Pkd2 gene, encoding the polycystin-2 protein, can be deleted specifically in kidney tubules. Pregnant dams received doxycycline beginning at embryonic day 13.5, which activated the Cre recombinase machinery and initiated tubule-specific gene deletion in the developing offspring. Because PKD is a ciliopathy, a disorder of the tiny cellular antennae called primary cilia, the investigators deliberately chose a kidney-restricted deletion strategy. This design choice matters: generalized ciliopathies can themselves disrupt neurodevelopment, since primary cilia are essential for oligodendrocyte maturation and granule cell proliferation in the brain. By restricting the genetic lesion to the kidney, the researchers could attribute any brain changes to kidney disease rather than to a direct developmental role of polycystin-2 in neural tissue.

The model proved devastatingly effective. By postnatal day 19, the PKD mice had blood urea nitrogen levels averaging 141 milligrams per deciliter, compared with just 21 milligrams per deciliter in controls, a more than sixfold elevation indicating severe renal failure. Their kidneys were riddled with cysts, with cystic tissue accounting for roughly 83 percent of total kidney area, versus under 5 percent in healthy littermates. Survival was also dramatically reduced: by postnatal day 20, only 20 percent of the PKD animals remained alive, while all controls survived. These figures confirm that the model recapitulates the severe, early-onset kidney disease seen in the most aggressive forms of pediatric PKD, and it does so within a timeframe that overlaps with the most dynamic phase of postnatal brain development.

With the disease phenotype firmly established, the team turned to neuroimaging. A total of five control and four PKD animals underwent longitudinal magnetic resonance imaging on postnatal days 9 and 19 using a 7 Tesla GE Discovery MR901 system, an ultra-high-field scanner capable of resolving fine anatomical detail in the tiny mouse brain. Anatomical imaging used a three-dimensional FIESTA sequence with an in-plane resolution of 104 square micrometers, while iron-sensitive T2* measurements relied on a two-dimensional multi-echo gradient echo sequence acquiring six echo times ranging from 2.5 to 22.5 milliseconds. Whole-brain T2* maps were generated by fitting a monoexponential decay curve to the echo images, and anatomical scans were normalized to the DSURQE Mouse Brain atlas using Advanced Normalization Tools, allowing precise region-of-interest measurements of both volume and relaxation time across the entire brain.

The volumetric results were, in a sense, reassuring: between postnatal days 9 and 19, there were no significant differences in brain volume between PKD and control mice in any region examined. The developing brains of the kidney-diseased animals were growing normally, at least by this gross anatomical measure. But the T2* data told a strikingly different story. Longitudinally, PKD mice showed significantly shorter T2* relaxation times across the total brain, global gray matter, and global white matter, with false discovery rate-adjusted p-values reaching below 0.01 for total brain and gray matter. The pattern extended to specific regions as well: the cerebral cortex, cerebellum, brainstem, hippocampus, and globus pallidus all displayed significantly shortened T2* relaxation times in the PKD group. Shorter T2* relaxation is the magnetic resonance signature of increased tissue iron, meaning that iron was accumulating throughout the brains of the kidney-diseased pups during a period when their brains otherwise appeared structurally normal.

Crucially, the imaging findings were not left to stand alone. The researchers euthanized the animals at postnatal day 19 and performed histological analysis on fixed brain sections using Perl’s Prussian blue staining, the century-old histochemical method that renders ferric iron as vivid blue deposits. The results confirmed the imaging: the cerebral cortex of PKD mice showed 33.4 percent positive staining for iron, compared with 17.9 percent in controls, a statistically significant increase. This convergence of quantitative MRI and direct histology is what elevates the study beyond prior human work, which could rely only on imaging surrogates. It provides the first histologically validated demonstration that early-life kidney disease drives measurable iron deposition in the brain, and it validates T2* MRI as a workable tool for tracking brain iron in neonatal animal models.

Why should failing kidneys cause iron to pile up in a newborn brain? The authors point to the well-documented disruption of iron metabolism in chronic kidney disease, particularly the role of hepcidin, the master hormonal regulator of iron homeostasis, which is elevated in CKD and promotes intracellular iron sequestration. When iron homeostasis breaks down, catalytic iron can participate in chemical reactions that generate free radicals, driving oxidative stress and inflammation. The consequences of excess brain iron are not hypothetical: in neurodegenerative conditions such as Parkinson’s disease and Huntington’s disease, increased iron deposition has been linked to iron-dependent cell death driven by lipid peroxidation, a form of regulated cell death known as ferroptosis. The possibility that a similar iron-mediated injury process operates in the developing brain of a child with kidney disease is precisely what makes these findings so consequential, and so unsettling.

The study is explicitly preliminary, and the authors are candid about its limitations. The sample size was small, only four PKD animals completed longitudinal imaging, and the false discovery rate correction threshold was set at 0.10 to reflect the exploratory nature of the work. Only male mice were included, since sex is a significant biological variable in brain development, meaning the findings await replication in females. T2* mapping itself is a surrogate marker rather than a direct measurement of iron content, and more specific techniques such as quantitative susceptibility mapping, though established in human imaging, have rarely been successfully implemented in early-life animal studies. The authors also note that alternative models, including surgical approaches like neonatal unilateral nephrectomy and genetic models using Hoxb7-Cre or Six2-Cre drivers, each carry their own trade-offs between genetic confounders, survival rates, and disease timing.

Nevertheless, the significance of the work lies in the platform it establishes. For the first time, researchers have a validated framework, combining a kidney-specific genetic model of pediatric PKD, longitudinal ultra-high-field T2* imaging, and histological confirmation, for studying how early-life kidney disease reshapes the chemistry of the growing brain. The findings extend prior human neuroimaging data into causal animal territory and open a concrete path toward investigating iron-mediated neuroinjury in pediatric chronic kidney disease. If abnormal iron metabolism proves to be a driving mechanism behind the neurocognitive deficits seen in children with CKD, it may eventually point toward interventions, whether iron-chelating strategies, anti-inflammatory approaches, or targeted modulation of hepcidin pathways, that could protect the developing brain during the most vulnerable window of a child’s life. For the families of children living with polycystic kidney disease, that possibility transforms a small mouse study into a genuinely hopeful line of inquiry.

Subject of Research: Brain iron deposition in a pediatric mouse model of autosomal dominant polycystic kidney disease

Article Title: Analysis of brain iron deposition in an in vivo model of pediatric autosomal dominant polycystic kidney disease

Article References: Steinbach, E. J. S., Lee, C.-Y., Magnotta, V. A., Lullmann, O., Poirier, M., Sowers, L. P., Xie, J., Huang, C.-L., & Harshman, L. A. (2026). Analysis of brain iron deposition in an in vivo model of pediatric autosomal dominant polycystic kidney disease. Pediatric Research. https://doi.org/10.1038/s41390-026-05485-4

Image Credits: AI Generated

DOI: 10.1038/s41390-026-05485-4

Keywords: polycystic kidney disease, chronic kidney disease, brain iron deposition, T2* MRI, pediatric neurodevelopment, Pkd2 knockout mouse, hepcidin, oxidative stress, Prussian blue staining, neonatal brain development, neurocognition, ferroptosis

The review, led by researchers including Peiwei Liu and supported by the National Natural Science Foundation of China, assembles evidence from mass spectrometry studies of isolated cilia in mammals and unicellular organisms to sketch the first broad map of ciliary membrane lipids. Primary cilia isolated from kidney-derived MDCK cells are enriched in cholesterol and its precursor desmosterol, apparently to reinforce membrane microdomains used for signal transduction. Motile cilia from porcine olfactory epithelium tell a different story: they lack cardiolipin, carry reduced amounts of phosphatidylethanolamine, and are enriched in sulfoglycosphingolipids, an adaptive profile thought to optimize the membrane for the mechanical stress of beating. In single-celled organisms the diversity is even more striking. The flagellar membrane of Trypanosoma brucei is rich in phosphatidylethanolamine, phosphatidylserine, ceramides, and sphingomyelin, while Chlamydomonas reinhardtii concentrates phytoceramide and ergosterol, lipids suited to photophysical processes and to ordered microdomains at the flagellar base.

Perhaps the most visually compelling finding concerns phosphoinositides, phosphorylated derivatives of phosphatidylinositol that form exquisitely organized rings within the cilium. Phosphatidylinositol 4,5-bisphosphate and phosphatidylinositol 3,4,5-trisphosphate localize to the transition zone, the molecular sieve at the ciliary base, where they occupy distinct subregions along the proximal-distal axis: PI(4,5)P2 sits closer to the basal body while PI(3,4,5)P3 occupies the distal portion. Phosphatidylinositol 4-phosphate, by contrast, is excluded from the transition zone and accumulates toward the ciliary tip. This polarized geography is not decorative. PI4P directly binds the C-terminus of the signaling protein Smoothened, driving the conformational change and phosphorylation required for Hedgehog pathway activation, one of the most conserved developmental signaling systems in animals. Cholesterol, meanwhile, can itself activate Smoothened through multiple binding domains, and its release from the receptor Patched 1 upon Hedgehog ligand binding is a central step in the cascade.

The review also confronts a stubborn technical controversy. Measurements of ciliary PI(4,5)P2 have produced conflicting results for years, with some studies detecting the lipid along the entire axoneme and others confining it strictly to the transition zone. The authors trace these discrepancies to permeabilization methods, microscopy techniques, and differences between antibodies and genetically encoded biosensors. Methanol fixation followed by confocal imaging spreads the signal along the axoneme, whereas Triton X-100 permeabilization or super-resolution STED microscopy restricts it to the transition zone. The field has not even agreed on whether low-level ciliary PI(4,5)P2 is physiological or pathological. The authors call for quantitative mass spectrometry, correlative light-electron microscopy, artificial intelligence-assisted artifact correction, and absolutely calibrated biosensors to settle the debate.

Beyond phosphoinositides, the review highlights cholesterol sequestration as a surprising regulatory mechanism. Using newly developed protein probes derived from bacterial toxins, researchers compared the ciliary membrane with the adjacent plasma membrane and found that the ratio of sphingomyelin to cholesterol is far higher in cilia, with accessible cholesterol present at extremely low levels. In other words, abundant sphingomyelin chelates cholesterol into a chemically inactive state. When sphingomyelin synthesis is inhibited, the trapped cholesterol is released and Hedgehog signaling is enhanced. This finding reframes the ciliary membrane as a buffered reservoir of sterol whose availability, not just abundance, controls signal output. Lipid rafts, the cholesterol- and sphingolipid-rich microdomains concentrated at the ciliary base, serve as platforms that gather GPI-anchored and acylated proteins, amplifying signaling, although the review notes that some ciliary proteins, such as adenylyl cyclase III and INPP5E, reach their destinations even when rafts are disrupted.

Lipids also act as molecular switches for building and dismantling the organelle itself. Phosphatidylserine on the trans-Golgi network recruits Rabin8 to initiate ciliary formation. Ceramides accumulate in an apical ceramide-enriched compartment above the basal body, and the enzyme SMPD4, which generates ceramide from sphingomyelin, is required for normal ciliary length; mutations in SMPD4 cause cilia shortening and are linked to cerebellar hypoplasia. Centrosomal PI4P must be cleared by the kinase PIPKIγ to allow recruitment of ciliogenesis factors such as TTBK2, while Golgi PI4P must be maintained by PI4KB to release Rab11a for delivery to centrioles. Distal PI(4,5)P2 controls ciliary length by regulating vesicle shedding at the tip. Even diet matters: a high-fat diet upregulates the enzyme SCD1, depleting palmitic acid needed for palmitoylation of ciliary proteins such as ARL13B and RAB8A in endothelial cells, while the same fatty acid accumulates in hypothalamic neurons, suppressing autophagy and shrinking their cilia. The microbiota-derived short-chain fatty acid butyrate, in contrast, promotes ciliogenesis in hunger-regulating neurons.

The clinical payoff of this basic science is substantial. In Bardet-Biedl syndrome, mutations in more than twenty genes disrupt the BBSome, a protein complex that balances lipid and protein traffic between the plasma membrane and the cilium. Loss of bbs1 in zebrafish photoreceptors causes free cholesterol to accumulate, and BBSome deficiency allows enzymes such as phospholipase D to build up inside cilia, altering their lipid composition. The authors propose a Fish Trap model in which the transition zone admits membrane proteins freely but blocks their exit, making BBSome-mediated export the only rescue route. In autosomal dominant polycystic kidney disease, cholesterol binding is essential for localizing the ion channel polycystin-2 to cilia, and the oxysterol 7β,27-dihydroxycholesterol gates the polycystin complex. Glycosphingolipids such as glucosylceramide and lactosylceramide are markedly elevated in polycystic kidneys. Zellweger syndrome, caused by peroxisome failure, starves cilia of cholesterol because peroxisomes normally ferry sterol along microtubules to the ciliary pocket, crippling Hedgehog signaling.

Phosphoinositide disorders complete the picture. Joubert syndrome, marked by the molar tooth sign on brain imaging, frequently stems from mutations in INPP5E, the enzyme that removes PI(4,5)P2 and PI(3,4,5)P3 from cilia. Without it, these lipids accumulate, disrupting the recruitment of the cargo adaptor TULP3 and derailing Hedgehog signaling. Intriguingly, different mutations in the same gene produce different diseases: catalytic-domain variants preserve ciliary targeting and cause Joubert syndrome, whereas C-terminal truncations destroy targeting but spare enzymatic activity, producing MORM syndrome with obesity and intellectual disability. Hydrolethalus syndrome, a lethal fetal ciliopathy, arises when mutant HYLS1 fails to activate PIPKIγ and clear centrosomal PI4P, simultaneously blocking ciliogenesis and Hedgehog signaling.

Therapeutically, the lipid angle is already yielding drugs. The glucosylceramide synthase inhibitor Genz-667161 alleviated obesity, retinal degeneration, and olfactory deficits in BBS mice while restoring ciliary structure and Hedgehog activity, and the related inhibitor Venglustat slowed cyst progression in polycystic kidney disease models. The approved MC4R agonist setmelanotide remains the core targeted therapy for BBS, though it requires dermatologic monitoring, and antisense oligonucleotides have restored protein expression in preclinical models of BBS16 splicing defects. A ketogenic diet improved kidney function in the KETO-ADPKD trial, and the PI3K inhibitor LY294002 partially rescued ciliary defects in zebrafish lacking inpp5e. The authors point to three frontiers: cryo-electron microscopy to resolve lipid-protein complexes at atomic resolution, deeper study of the cilia-metabolism axis linking ciliary dysfunction to obesity and dyslipidemia, and dynamic mapping of ciliary lipid rafts with spatial lipidomics and super-resolution imaging. What was once an afterthought of cilia biology, the membrane itself, is now the most promising therapeutic frontier in the field.

Subject of Research: Lipid homeostasis of the ciliary membrane and its role in cilia function and ciliopathies

Article Title: Ciliary Membrane Lipid Homeostasis in Health and Disease

Article References: Ciliary Membrane Lipid Homeostasis in Health and Disease. (n.d.). https://doi.org/10.1002/advs.77971

Image Credits: AI Generated

DOI: 10.1002/advs.77971

Keywords: cilia, ciliary membrane, lipids, cholesterol, phosphoinositides, ceramide, Hedgehog signaling, ciliopathies, Bardet-Biedl syndrome, polycystic kidney disease, Joubert syndrome, lipid rafts

ARPKD affects roughly one in 20,000 children. The disease causes liquid-filled cysts to form in the kidney, and those cysts can appear even before a child is born. For newborns, they can be life-threatening, and for some patients the damage accumulates until the kidneys fail before adulthood. The segment of the kidney primarily affected is the collecting duct, the network of tubules responsible for draining urine from the organ. Because the disease is rare and its cellular origins are difficult to access in living patients, researchers have long lacked the experimental systems needed to watch the disease unfold at the cellular level, let alone to screen potential therapies against it. Li’s project is designed to close that gap.

The strategy rests on two complementary types of lab-grown biological systems, both derived from human stem cells. The first is the organoid, a three-dimensional structure grown from a type of progenitor cell that gives rise to the collecting duct system. In a Petri dish, these organoids self-organize into elongated tubules that closely mimic the architecture and function of human collecting duct tissue. The second is the assembloid, a more complex construct grown by combining collecting duct progenitor cells with cells that develop into the kidney’s filtering units, allowing two distinct compartments of the organ to be modeled together. With success, the project’s organizers say, these systems could become a major enabling factor for basic, translational and clinical research tackling ARPKD.

The power of the organoid approach lies in scale and speed. Because the structures are grown from human cells in culture, researchers can manufacture hundreds of thousands of them cost-effectively, according to Li. That opens the door to high-throughput drug screening, in which vast libraries of candidate compounds can be evaluated simultaneously against diseased tissue. Instead of testing one drug at a time in slow and expensive animal studies, scientists can rapidly identify the most promising molecules in vitro and then advance only the strongest candidates. For a disease as rare as ARPKD, where commercial incentives for drug development are limited, such a screening platform could dramatically lower the barriers to discovering new therapies.

The assembloid arm of the project addresses a different and equally stubborn problem in drug development: the failure of treatments that looked promising in the lab but collapsed in clinical trials. Li points to two major reasons such failures occur, kidney toxicity and the biological differences between animal models and human patients. His team’s plan is to grow diseased human kidney tissue in the form of assembloids and transplant it into mice, creating what researchers describe as a humanized model of the disease living inside an animal host. Drugs tested against that tissue would, in principle, yield far more accurate predictions of both efficacy and safety in human patients than conventional animal models can provide, because the target tissue itself would be human.

The project does not begin from scratch. Li’s research group has already developed a collecting duct organoid that closely mimics the structure and function of human tissue, and the team has shown that it can effectively model a related, more common condition: autosomal dominant polycystic kidney disease, or ADPKD. ADPKD accounts for about 90 percent of all polycystic kidney disease cases and is generally a milder illness that tends to emerge during adulthood rather than before birth. Having modeled ADPKD both in Petri dishes with collecting duct organoids and in mice with assembloids, the researchers now plan to apply the same principles to ARPKD, adapting systems they have already validated to a rarer and more severe form of the disease.

International collaboration supplies another key ingredient. Cell lines carrying ARPKD-related mutations were provided by the two researchers who developed them: Yun Xia, PhD, of Singapore’s Agency for Science, Technology and Research, and Ryuji Morizane, MD, PhD, of Harvard Medical School. These mutated cell lines serve as the starting material from which the diseased organoids and assembloids will be grown, embedding the genetic defects that drive cyst formation into the lab-grown tissue itself. Li has described the generosity of these colleagues as a perfect example of how the research community works together to help patients, a reminder that progress on rare diseases often depends on scientists sharing hard-won tools across institutions and continents.

The grant also reflects a deliberate strategic bet by the funder. The PKD Foundation, founded in 1982, is the only organization in the United States solely dedicated to finding treatments and a cure for polycystic kidney disease, and it is the largest private funder of research into the illness. Susan Bushnell, the foundation’s president and CEO, said that the field is seeing unprecedented momentum in PKD research and that the organization believes this is the right time to invest boldly in the scientists working to change the future of the disease. Because of the generosity of donors, she noted, the foundation is able to increase its investment in promising research that represents hope for the millions of people and families living with PKD.

For Li, the ARPKD project is one milestone within a much larger scientific mission. For nearly 15 years, he has worked on coaxing stem cells to produce kidney-like structures, with the long-term goal of engineering an artificial kidney for patients awaiting an organ transplant. The scale of that unmet need is enormous: kidneys account for about 80 percent of the demand for donor organs, and more than 90,000 people are on the kidney donation waitlist in the United States alone. Engineering a transplantable kidney, Li has said, is the ultimate goal of his career, but along the way, developing kidney-like tissue in which disease can be modeled and new therapies found offers the chance to meaningfully benefit patients with kidney disease now.

The significance of the work extends beyond a single rare disease. If collecting duct organoids and kidney assembloids prove reliable models for ARPKD, the same platforms could accelerate research into ADPKD and other disorders of the kidney’s tubular and filtering systems, and could sharpen the preclinical testing pipeline for any drug destined for the kidney. The approach also illustrates a broader shift in biomedical science, as human stem cell-derived tissues increasingly replace or supplement animal models whose biology often fails to translate to patients. For the families facing ARPKD, a condition that currently offers few answers, the grant represents something concrete: a funded, technically grounded path toward the models that drug discovery requires, built from the very cells where the disease begins.

Subject of Research: Development of human stem cell-derived organoid and assembloid models for autosomal recessive polycystic kidney disease research

Article Title: PKD Foundation provides support for kidney disease research by USC Stem Cell’s Zhongwei Li

Article References: PKD Foundation provides support for kidney disease research by USC Stem Cell’s Zhongwei Li. (n.d.). Original publication

Image Credits: AI Generated

DOI: Not provided

Keywords: polycystic kidney disease, ARPKD, organoids, assembloids, stem cells, kidney disease, PKD Foundation, drug screening, collecting duct, USC Stem Cell, genetic disease, transplantation

The central challenge the team confronted is a notorious one in human genetics. PKD1 shares extensive stretches of near-identical sequence with six pseudogenes located elsewhere on chromosome 16, remnants of duplicated DNA that have lost their protein-coding function. Any sequencing approach that reads the genome indiscriminately risks aligning true PKD1 reads to the wrong location or, worse, mistaking pseudogene sequence for genuine gene sequence, producing false calls that could mislead clinical decisions. To sidestep this interference, the researchers employed long-range PCR, a technique that selectively amplifies the functional PKD1 gene in large fragments before sequencing, effectively isolating the target from its deceptive copies.

Oxford Nanopore Technology has attracted growing interest in clinical genomics because of its accessibility. A MinION device is roughly the size of a large USB stick, requires comparatively modest capital investment, and can be run in laboratories far from major sequencing centers. The trade-off has always been accuracy: nanopore reads carry higher error rates than the short-read Illumina platforms that dominate clinical laboratories, because each DNA strand threads through a protein pore and is read base by base as electrical current fluctuations. Raw errors, however, are largely random rather than systematic, which means that reading the same molecule many times and applying sophisticated computational correction can drive the consensus error rate down to levels suitable for variant calling. The catch is that this correction demands careful bioinformatic optimization, and until now no validated, end-to-end pipeline existed specifically for PKD1 on the nanopore platform.

The Chilean team built their solution as a nine-stage bioinformatic pipeline, with each stage dedicated to a distinct computational task in the journey from raw electrical signal to final variant call. The stages encompass the standard architecture of modern long-read analysis: quality assessment of the raw data, basecalling that converts current measurements into DNA sequence, demultiplexing to sort reads by sample, adapter trimming and filtering to remove artifacts, alignment of reads to the human reference genome, post-alignment processing, variant calling, and annotation that interprets each variant’s likely biological consequence. Crucially, rather than adopting tools by default, the authors performed a systematic, criteria-based selection at every stage, comparing candidate programs against explicit performance benchmarks to choose the configuration best suited to the error profile of nanopore data derived from long-range PCR amplicons.

This structured development approach is what distinguishes the work from ad hoc bioinformatics. Nanopore pipelines are notoriously sensitive to parameter choices: the settings that work for whole-genome sequencing of bacteria may fail badly when applied to a single amplified human gene, where coverage is deep, read lengths are constrained by the PCR fragment size, and homopolymer stretches, runs of identical bases that nanopore sequencers historically struggled to measure, can distort indel calls. By evaluating tools stage by stage against defined criteria, the team produced a reproducible framework whose behavior can be understood and audited, an essential property for any pipeline intended for clinical use. The pipeline was also designed with computational efficiency in mind, so that it can run on modest hardware rather than demanding a high-performance computing cluster, although the authors acknowledged the Patagn supercomputer team for supporting their development work.

Validation proceeded in two independent cohorts with distinct purposes. The first consisted of eight samples in which PKD1 variants had already been confirmed by Sanger sequencing, the decades-old method that reads DNA through chain-termination chemistry and remains the reference standard in many clinical laboratories. The optimized nanopore pipeline achieved complete concordance with Sanger across all eight samples, correctly recovering every previously known variant without introducing false positives. This head-to-head agreement is the critical benchmark for any platform aspiring to clinical deployment, because it demonstrates that the computational corrections have neutralized the platform’s raw error rate to the point where the two technologies deliver identical answers on real patient material.

The second cohort provided the true test of diagnostic utility: 26 ADPKD patients who had never received a molecular diagnosis. When the pipeline was applied to their sequenced samples, it identified pathogenic or likely pathogenic PKD1 variants in 69 percent of cases, a detection rate consistent with the known genetics of ADPKD, in which PKD1 accounts for the large majority of cases with an identifiable cause and roughly a tenth of patients carry variants in PKD2 or other genes instead. Among the prioritized findings were six variants never before reported, expanding the catalog of known disease-causing mutations in the gene. To confirm these new calls, the researchers sent 18 prioritized variants for independent Sanger verification, and 17 were confirmed, a validation rate that underscores both the sensitivity of the pipeline and the value of orthogonal confirmation for novel discoveries.

The implications reach well beyond a single gene. ADPKD is one of the most common inherited kidney diseases worldwide, and targeted therapies now exist that can slow disease progression, making early molecular diagnosis clinically meaningful rather than merely informative. Yet in many countries, including Chile where this study was conducted, patients may wait years for genetic testing or never receive it, because sending samples to commercial laboratories abroad is costly and short-read sequencing of PKD1 requires careful strategies to handle the pseudogene problem. A pipeline that runs on a benchtop nanopore device, uses long-range PCR to guarantee specificity, and delivers Sanger-concordant results changes the calculus for public health systems, allowing regional hospitals and university laboratories to perform the analysis in-house at low infrastructure cost.

The work also offers a template for tackling other clinically important genes haunted by pseudogenes or other architectural complexities. Many disease genes share this burden, and the authors argue that their structured, criteria-based development approach, demonstrated diagnostic performance, and computational optimization make the framework applicable to genomic research and clinical settings requiring high-sensitivity analysis of large, complex genes. Because the pipeline is described as reproducible and its development logic is documented stage by stage, other groups can adapt it rather than rebuilding the analysis from scratch, accelerating the spread of long-read diagnostics into low-resource environments.

The study, conducted under ethical approval from the Research Ethics Committee of the Health Service of Valdivia and with informed consent from all participants recruited across Chilean health centers, was supported by Chile’s National Agency for Research and Development through FONDECYT Regular projects and by Innovation Fund for Competitiveness grants from the Regional Government of Los Ros. The authors credit collaboration among the Nephrology Laboratory of Universidad Austral de Chile, the Valdivia Base Hospital, the Centro de Investigacin Clnica Avanzada, and nephrologists across the country who connected patients with the research. As nanopore sequencing matures from a promising technology into a validated clinical tool, this pipeline stands as evidence that careful bioinformatics, not expensive hardware, can be the decisive factor in bringing precision diagnosis to patients who have historically been left waiting.

Subject of Research: Development and clinical validation of an Oxford Nanopore bioinformatic pipeline for detecting PKD1 variants in autosomal dominant polycystic kidney disease

Article Title: An optimized nanopore-based bioinformatic pipeline for PKD1 variant detection: development and validation with clinical samples

Article References: Millar, D., Gajardo, M., Poblete, B., Ubilla, R., Izquierdo, M., Medina, A., Lehmann, P., Flores, C., Krall, P., & Maturana, J. (2026). An optimized nanopore-based bioinformatic pipeline for PKD1 variant detection: development and validation with clinical samples. BMC Bioinformatics. https://doi.org/10.1186/s12859-026-06644-4

Image Credits: AI Generated

DOI: 10.1186/s12859-026-06644-4

Keywords: Oxford Nanopore Technology, PKD1, ADPKD, long-read sequencing, bioinformatic pipeline, variant detection, pseudogene, long-range PCR, Sanger sequencing, polycystic kidney disease, low-resource sequencing, clinical genomics